Objective. The aim of this study was to investigate the relationship between different disease activity indices (DAIs) and their individual components and radiographic progression in patients with RA.
Introduction
RA is a chronic inflammatory disease that may cause severe disability, reduction in quality of life and premature mortality [13] , usually demonstrated by conventional radiography [4] . In addition, disease activity has been shown to be closely related to joint damage. Therefore the current treatment target in RA is controlling disease activity and achieving remission [5] .
The principal manifestations of disease activity (swelling, tenderness, pain, stiffness and elevated acute phase reactants) can be measured separately using instruments or scales or in different combinations through composite disease activity indices (DAIs) [6] . Today the use of DAIs is recommended over separate instruments, in both clinical trials and clinical practice, as part of treat-to-target strategies, since they are more reliable and responsive to change. Most of the DAIs include a patient-reported assessment, a physician-assessed instrument and sometimes an acute phase reactant. However, some consider patient-reported outcomes, either as single measures or aggregated in a composite score, more feasible to monitor disease activity in a clinical setting because a physical examination is not required [6, 7] . The association between these separate measures of disease activity and radiographic progression is important in deciding which measure should be used to monitor disease activity in patients with RA. Although some studies have provided some evidence in respect of this, this point is still unclear. The objective of this study was to investigate the relationship between the different DAIs and their individual components and radiographic progression in patients with RA.
Methods

Research question and search strategy
A systematic literature review was performed using Medline and Embase databases in collaboration with an experienced librarian. The research question was formulated according to the Population, Intervention, Comparison, Outcome and Study design method [8] in which each of the items was defined as follows: population: patients with RA; intervention: DAIs including the DAS, the 28-joint DAS (DAS28), the Simplified Disease Activity Index (SDAI), the Clinical Disease Activity Index (CDAI), the Rheumatoid Arthritis Disease Activity Index (RADAI) and the Routine Assessment of Patient Index Data (RAPID) as well as individual instruments or scales including tender joint count (TJC), swollen joint count (SJC), patient's general health (GH) assessment, patient's global assessment (PGA), patient's visual analogue scale of pain (pain VAS), evaluator's global assessment (EGA), CRP and ESR; outcome: radiographic progression measured by any scoring method assessing erosions and/or joint space narrowing on conventional radiographs of the hands and/or feet; setting: longitudinal studies with at least 12 months of follow-up.
The search did not have any limit for starting date and included published studies up to 31 July 2013 . No language restriction was applied. The search terms are provided in supplementary Table S1 , available at Rheumatology Online.
Selection of studies
Two reviewers (V.N.C. and A.M.G.) independently screened the titles and abstracts of the citations and selected articles for full-text review. If there was no consensus between the two reviewers about including a particular study, the article was retrieved and included for full-text review. Later, both readers decided whether or not to include a study for data extraction after reading the full text of the article. In the case of lack of agreement, consensus was sought by discussion. Inclusion criteria were prospective or retrospective cohort studies or randomized controlled trials (RCTs) including only patients with RA or reporting separate data for them, available data for at least 50% of the initial sample size, an evaluation of the relationship between any of the DAIs or instruments described under intervention in the search and radiographic progression and assessment of radiographic progression on conventional radiographs after a minimum of 12 months. No limitation for the type of analysis performed in the studies was used. However, a statistical hierarchy based on the use of the disease activity measure as an independent variable in the analysis (time-integrated measures were considered more appropriate than only baseline measures) and the type of analysis (multivariable was considered more appropriate than univariable) was taken into account for the results of this systematic review and to elaborate conclusions. For studies testing multivariable analysis, a minimum of 50 patients was required to be included. The exclusion criterion was lack of sufficient data reported in order to assess the relationship between the DAIs or single instruments and radiographic progression.
Data extraction
Using a systematic data extraction form developed for this specific purpose, both reviewers independently extracted data for each study, including sociodemographic and disease characteristics, radiographic assessment, degree of disease activity at baseline and during follow-up and statistically relevant data (estimate and significance) for the reported relationship between disease activity measures and radiographic progression. Further, they also evaluated the quality and potential biases of the studies using the guidelines for assessing quality in prognostic studies, assigning an overall quality score per study of between 0 and 6 points according to Hayden et al. [9] .
Data synthesis
Data were summarized in two groups: DAIs and separate instruments were classified based on the way of measuring (time integrated or baseline) and the type of analysis (multivariable or univariable) used. The relationship between disease activity measures and the outcome was shown in most of the studies as odds ratio, coefficients (b) or positive likelihood ratio with a corresponding P-value or 95% CI.
Results
Characteristics of the studies A detailed flowchart with the results of the literature search is depicted in supplementary Fig. S1 , available at Rheumatology Online. The search retrieved 1232 hits and 57 studies were included for data extraction [1066] . The principal characteristics and overall quality score of the studies are shown in supplementary Table S2, available at Rheumatology Online. Forty of these studies were observational studies and 18 used data from RCTs. Sample size ranged from 13 to 1433 patients. Supplementary  Table S3 , available at Rheumatology Online, presents the demographic and disease characteristics as well as the treatment for patients included in each study. The mean age of patients included in the studies ranged from 37 to 64 years and the percentage of female patients was between 59% and 100%. Most patients included in the studies were RF positive (range 48100%) and anti-CCP antibody positive (3290%). Of all the studies reporting disease duration, most had a symptom duration of <2 years (range 2.7158 months). Further, most of the studies included patients receiving a synthetic DMARD (sDMARD). Most of the studies (70%) were prospective cohorts and had an overall quality score of at least 4 points (out of a maximum of 6; range 36). Radiographic progression was mainly assessed using the modified Sharpvan der Heijde or Larsen scoring method, and the time period to evaluate progression was between 12 and 240 months (supplementary Table S4 , available at Rheumatology Online). The degree of disease activity and functional status at the baseline visit of patients included in the studies are presented in supplementary Table S5 (single instruments)  and supplementary Table S6 (DAIs), available at Rheumatology Online, and considering the mean values of the DAIs, all studies reporting disease activity included patients with active disease. Table 1 shows the results for the studies that investigated the relationship between any of the DAIs and radiographic progression.
DAIs
DAS and DAS28
Eleven studies evaluated the relationship between DAS and radiographic damage. Most of the studies (8 of 11) assessed the association between DAS at baseline and radiographic progression and used univariable testing. Six of the eight (75%) studies did not show a statistically significant association. However, the three studies assessing the relationship between time-integrated DAS and radiographic progression used multivariable testing and showed a significant relationship.
Eighteen studies reported results for the association between DAS28 and radiographic damage. Among the studies that investigated the relationship to baseline DAS28, only one of six (17%) studies employing univariable analyses and one of two using multivariable analyses reached statistical significance. Further, 10 studies (6 with univariable and 4 with multivariable testing) evaluated the relationship for the time-integrated DAS28 and they all observed a significant relationship with progression of radiographic damage.
SDAI and CDAI
Seven studies (six with univariable and one with multivariable analyses) reported results for the relationship between baseline (n = 1) or time-integrated (n = 6) SDAI and the progression of joint damage and all of them showed statistically significant associations.
Five studies (four with univariable and one with multivariable analyses) investigated the relationship between baseline (n = 1) or time-integrated (n = 4) CDAI and radiographic progression and all except one (with a similar trend) showed a significant association.
RADAI and RAPID
Only two studies evaluated the effect of the RADAI at baseline as a predictor of radiographic damage, one of which showed a significant relationship. Moreover, no study investigating the relationship between RAPID and radiographic progression was found.
Individual instruments
TJC and SJC
The results for those studies evaluating the relationship between TJC and SJC and radiographic progression are shown in Table 2 . A total of 25 studies provided TJC results. Most of these studies (16 of 25) assessed the relationship with TJC at baseline and used univariable analysis. Eleven of the 16 studies did not report a statistically significant association. Furthermore, 6 of 25 studies reported a relationship between the time-integrated TJC and radiological progression, but only a significant univariate relationship was found. In addition, 33 studies investigated the relationship between SJC and progression of joint damage. Among these, the majority (19 of 33) evaluated only SJC at baseline and applied univariable statistical testing. Twelve of the 19 studies did not show a significant association. On the other hand, most of the studies evaluating the relationship between time-integrated SJC or using multivariable analysis observed a significant relationship.
Patient-reported outcomes (GH, PGA and pain VAS) and EGA
A summary with the results for these individual instruments is presented in Table 3 . Concerning the association with GH, only two studies evaluating the predictive value of baseline GH for radiographic progression were found: one study with univariable analysis did not observe an association, while another study with multivariable analysis found a weak but statistically significant relationship. Four studies all using univariable testing reported results for PGA and the two of them that assessed time-integrated PGA reached statistical significance. Moreover, eight studies evaluated the association of radiographic progression with pain VAS. Most of them (six of eight) only used the baseline measure and did not report a significant relationship. Among the two studies that employed time-integrated pain VAS, only the one with univariable testing reached statistical significance.
Seven studies investigated the association between EGA and radiographic progression. Most of the studies (four of five) using the baseline measure did not observe a significant relationship, while the two studies evaluating the association with time-integrated EGA found a significant relationship. Tables 4 and 5 show the results for studies investigating the relationship between ESR and CRP and radiographic progression. A total of 37 studies reported results for ESR. Among the studies assessing the relationship with baseline ESR (26 of 37), a significant relationship was observed in 6 of the 14 studies using univariable analysis and in the majority (10 of 12) of the studies with multivariable analysis. Furthermore, most of the studies (9 of 11) evaluating A total of 35 studies reported results for CRP. Of those studies, 25 evaluated only the association for baseline CRP. The results were inconsistent since 8 of 17 studies with univariable analysis and 5 of 8 studies with multivariable testing observed a significant relationship between CRP and radiographic progression. Among the studies assessing the relationship between time-integrated CRP and progression of joint damage, four of six with univariable analysis and two of four with multivariable testing reached statistical significance, with no differences based on the mean disease duration of patients included in the studies. As a summary of the main results of this review, Table 6 shows the number of studies that assessed each specific DAI or individual instrument as well as the percentage of studies that reached statistical significance grouped by the method of measuring disease activity parameters and the analysis they employed.
ESR and CRP
Finally, only six studies (four with univariable and two with multivariable analysis) stratified their results based on treatment and differentiated between patients receiving an sDMARD and patients receiving a biologic DMARD in monotherapy or in combination with an sDMARD. Visser et al. [39] did not find differences between the two groups for the DAS, TJC, SJC, ESR and CRP at baseline. did not find differences for baseline SJC and CRP. Lastly, three studies (two with multivariable testing) found differences between the two treatment groups for the SJC and ESR/CRP at study entry and one of them also showed this difference for the SDAI [10, 21, 44] . The relationship between these instruments and radiographic progression was only significant in the group of patients receiving sDMARDs.
Discussion
The findings of this review suggest that DAIs are more consistently and closely related to radiographic progression than their separate components. Furthermore, the number of studies assessing the different DAIs varies and therefore it is difficult to decide which of the DAIs performs better in this sense. While the association with DAS, and especially with DAS28, has frequently been investigated, only a few studies have evaluated the relationship between the SDAI and CDAI and radiographic progression, with similar results for both (SDAI and CDAI) indices. At this time there is insufficient evidence for the relationship between the RADAI and radiographic progression, and the RAPID has not yet been evaluated in this regard. Among the single-item instruments, only those reflecting inflammation-SJC and ESR-have been shown with sufficient evidence to be associated with radiographic progression. Most of the studies have not observed an association with patient-reported outcomes such as pain VAS or with other subjective measures such as TJC. Published data for GH, PGA and EGA are limited and do not support their use as unique tools related to progression of joint damage. Furthermore, data for CRP are less consistent and therefore ESR seems to be a better measure related to radiographic progression in RA. This observation was independent of disease duration.
Today, the claim is that biologic therapy may disconnect the relationship between disease activity and joint damage [67] . This means that despite a lack of improvement in disease activity parameters, patients receiving this therapy still show an inhibition of radiographic progression. Furthermore, a recent meta-analysis has suggested that this effect may not be limited to biologic therapy and could also be induced by conventional therapies [68] . In this review, only six studies assessed separately the relationship between disease activity variables and radiographic progression in both biologic and conventional treatment. The two studies using multivariable analysis assessed baseline measures of disease activity and support the theory that only biologic therapy disconnects this relationship [21, 42] . However, the remaining four studies applied univariable analyses and only one of them showed a different relationship based on therapy [10, 15, 18, 39] . Most of the studies in this systematic review included patients receiving sDMARDs. Therefore more data are required to clarify whether the relationship found between all the DAIs or instruments and radiographic progression may be different in patients receiving biologic therapy. Further methodological limitations of this review should be considered. While a hierarchy was considered to classify the published evidence and to elaborate the conclusions, the results of our study are based simply on whether or not the relationship between baseline or time-integrated disease activity measures and radiographic progression was statistically significant. Other potentially relevant factors such as the sample size or the quality of the study were not taken into account. In any case, it is not only a difference in sample size between the studies that explains the main results: in general, studies with a significant relationship did not necessarily have a greater number of patients than studies without a significant relationship. In addition, the estimate for each of the studies is shown in the tables of this review, but it was not considered appropriate to make direct comparisons, as different types of estimate have been applied. Another limitation could be publication bias. However, publication bias usually occurs if negative findings are not published. So if present, this would most likely confirm the absence of a relationship for the measures that do not show a relationship in the published literature.
Also, different scoring methods were used to assess radiographic progression, resulting in a different definition of outcome across studies. Finally, the majority of studies included patients with early disease and therefore it is not possible to investigate whether the relationship between DAI and radiographic progression is the same in patients with early and established RA.
In summary, published evidence indicates that DAIs are related to radiographic progression and thus have greater validity regarding a key construct of RA, i.e. that disease activity is related to structural damage. Among the single instruments, only measures reflecting inflammation, such as SJC and ESR, and not patient-reported measures are robustly associated with radiographic progression. Based on these results, we recommend the use of one of the DAIs that assess at least the number of swollen joints to monitor disease activity in patients with RA.
Rheumatology key messages
. All disease activity indices that include swollen joints are related to radiographic progression in RA. . Swollen joint count and acute-phase reactants are the only instruments robustly associated with radiographic progression in RA. . Disease activity indices that assess at least the swollen joint count are recommended to monitor disease activity in RA.
